Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019

Blake Anderson; Zirka Smith; Srilatha Edupuganti; Xiaobo Yan; Christopher M Masi; Henry M Wu

doi:10.1093/ofid/ofab315

Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019

Open Forum Infect Dis. 2021 Jun 12;8(7):ofab315. doi: 10.1093/ofid/ofab315. eCollection 2021 Jul.

Authors

Blake Anderson¹, Zirka Smith², Srilatha Edupuganti², Xiaobo Yan³, Christopher M Masi¹, Henry M Wu²

Affiliations

¹ Division of General Internal Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
² Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
³ Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

Abstract

We compared rates of emergency department visits or hospitalizations among ambulatory coronavirus disease 2019 (COVID-19) patients treated with monoclonal antibody (mAb) therapy (n = 305) vs untreated patients (n = 6354). Treatment was associated with decreased encounters within 30 days (adjusted odds ratio, 0.23 [95% confidence interval, .15-.36]). Our findings support treatment of acute COVID-19 with mAbs.

Keywords: COVID-19; SARS-CoV-2; monoclonal antibodies; therapeutics.